Prostate specific antigen density of the transition zone for early detection of prostate cancer

被引:99
|
作者
Djavan, B [1 ]
Zlotta, AR
Byttebier, G
Shariat, S
Omar, M
Schulman, CC
Marberger, M
机构
[1] Univ Hosp Vienna, Dept Urol, Vienna, Austria
[2] Univ Clin Brussel, Erasme Hosp, Dept Urol, Brussels, Belgium
来源
JOURNAL OF UROLOGY | 1998年 / 160卷 / 02期
关键词
prostate-specific antigen; prostatic neoplasms;
D O I
10.1016/S0022-5347(01)62911-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We compare the ability of several prostate specific antigen (PSA) parameters, including PSA density of the whole prostate and of the transition zone, percent free PSA and PSA velocity, to enhance the specificity for prostate cancer detection and to reduce unnecessary biopsies in men with serum PSA levels of 4 to 10.0 ng./ml. Materials and Methods: This prospective study included 559 consecutive men referred for early prostate detection or lower urinary tract symptoms who had a serum PSA of 4.0 to 10.0 ng./ml. All men underwent prostatic ultrasonography and sextant biopsy with 2 additional transition zone biopsies. Specific biopsies of abnormal findings on digital rectal examination were also performed. In all cases if first biopsies were negative an additional set of biopsies was performed within 6 weeks. The ability of PSA density, PSA transition zone, PSA velocity and percent free PSA to improve the power of PSA in the detection of prostate cancer was evaluated with univariate and multivariate analyses as well as receiver operating characteristics (ROC) curves. Results: Of 559 patients 342 had histologically confirmed benign prostatic hyperplasia and 217 had prostate cancer. Mean serum PSA, PSA velocity, PSA density and PSA transition zone were statistically higher (p <0.018, p <0.037, p <0.0001 and p <0.0001, respectively) and percent free PSA was statistically lower (p <0.0001) in patients with prostate cancer than in those with benign disease. Multivariate analysis and ROC curves showed that PSA transition zone and percent free PSA were the most powerful and highly significant predictors of prostate cancer. Areas under the ROC curve for PSA transition zone and percent free PSA were 0.827 and 0.778, respectively (p = 0.01 McNemar test). Combination of free-to-total PSA with PSA transition zone significantly increased the area under the ROC curve compared to PSA transition zone alone (p = 0.020). With a 95% sensitivity for prostate cancer detection a PSA transition zone cutoff of 0.25 ng./ml./cc would result in the lowest number of unnecessary biopsies (47% PSA transition zone specificity) compared to all other PSA parameters. However, total prostate volume (greater than 30 cc in 422 men or less than 30 cc in 137) was an important factor in predicting the statistical performance of PSA transition zone. In fact, PSA transition zone did not outperform free percent PSA in sensitivity and specificity when the entire prostate gland volume was less than 30 cc (p = 0.094 McNemar test). Conclusions: PSA density of the transition zone enhances the specificity of serum PSA for prostate cancer detection in referred patients with a serum PSA of 4.0 to 10.0 ng./ml. compared to other PSA parameters currently available. While PSA transition zone was more effective in prostates greater than 30 cc and percent free PSA was more effective in prostates less than 30 cc, the combination of percent free PSA with PSA transition zone further increased prostate cancer prediction.
引用
收藏
页码:411 / 418
页数:8
相关论文
共 50 条
  • [21] Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy: The usefulness of complexed prostate specific antigen adjusted for transition zone volume
    Horinaga, M
    Nakashima, J
    Ishibashi, M
    Oya, M
    Ohigashi, T
    Marumo, K
    Murai, M
    JOURNAL OF UROLOGY, 2002, 168 (03): : 986 - 990
  • [22] Value of Prostate-Specific Antigen and Prostate-Specific Antigen Density in Detection of Prostate Cancer in an Iranian Population of Men
    Ghafoori, Mahyar
    Varedi, Peyman
    Hosseini, Seyed Jalil
    Asgari, Mojgan
    Shakiba, Madjid
    UROLOGY JOURNAL, 2009, 6 (03) : 182 - 188
  • [23] Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels
    Furuya, Y
    Ohta, S
    Sato, N
    Kotake, T
    Sugano, I
    Nagao, K
    Masai, M
    ANTICANCER RESEARCH, 2001, 21 (2B) : 1317 - 1320
  • [24] The role of prostate-specific antigen velocity in prostate cancer early detection
    Potter S.R.
    Carter H.B.
    Current Urology Reports, 2000, 1 (1) : 15 - 19
  • [25] Update on prostate-specific antigen testing for the early detection of prostate cancer
    Terrell, John D.
    Roehrborn, Claus G.
    Wians, Frank H., Jr.
    Karakiewicz, Pierre I.
    Shariat, Shahrokh F.
    LABMEDICINE, 2008, 39 (10): : 613 - 621
  • [26] What is the future of prostate-specific antigen for the early detection of prostate cancer?
    Getzenberg, Robert
    BJU INTERNATIONAL, 2008, 102 (02) : 157 - 158
  • [27] Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: Results of the prospective multicenter European trial
    Djavan, B
    Remzi, M
    Zlotta, AR
    Ravery, V
    Hammerer, P
    Reissigl, A
    Dobronski, P
    Kaisary, A
    Marberger, M
    UROLOGY, 2002, 60 (4A) : 4 - 9
  • [28] Prostate specific antigen adjusted for transition zone epithelial volume: The powerful predictor for the detection of prostate cancer on repeat biopsy
    Ohigashi, T
    Kanao, K
    Kikuchi, E
    Nakagawa, K
    Nakashima, J
    Marumo, K
    Murai, M
    JOURNAL OF UROLOGY, 2005, 173 (05): : 1541 - 1545
  • [29] Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer
    Ankerst, Donna Pauler
    Gelfond, Jonathan
    Goros, Martin
    Herrera, Jesus
    Strobl, Andreas
    Thompson, Ian M., Jr.
    Hernandez, Javier
    Leach, Robin J.
    JOURNAL OF UROLOGY, 2016, 196 (02): : 355 - 360
  • [30] Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: Do combination tests improve detection?
    Etzioni, R
    Falcon, S
    Gann, PH
    Kooperberg, CL
    Penson, DF
    Stampfer, MJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (10) : 1640 - 1645